Insulet Corporation (NASDAQ: PODD) has announced the full U.S. market release of Omnipod Discover, a web-based data platform designed for users of its Omnipod 5 automated insulin delivery system, their caregivers, and healthcare professionals.

The platform converts diabetes data into visualizations and personalized insights, and delivers weekly glucose and insulin delivery reports to users' smartphones. For healthcare professionals, the platform overlays a licensed Ambulatory Glucose Profile with adjustable pump settings and bolus events to support clinical decision-making.

According to the company, more than 15,000 Omnipod 5 users and over 1,800 healthcare professionals had already adopted the platform during a limited U.S. market release program. Omnipod Discover is also available in Spain, Australia, Saudi Arabia, Qatar, Kuwait, the UAE, and Israel.

In June, Insulet presented real-world data at the American Diabetes Association's Scientific Sessions in New Orleans, showing that use of Omnipod Discover was associated with improvements in time in range, with 32% of users experiencing a clinically meaningful increase of 3% or more.

"The future of diabetes care is not just about generating more data, it's about making that data meaningful," said Dr. Trang Ly, Senior Vice President and Chief Medical Officer at Insulet. "Omnipod Discover simplifies data review for Omnipod 5 users and their healthcare providers so they spend less time gathering information and more time collaborating on diabetes management."

The platform is now available to all Omnipod 5 users nationwide. Existing users can enroll through PodderCentral, while healthcare professionals can register through their dedicated Omnipod sales representative.